# EDGAR Filing Document

**Accession Number:** 0001425205
**File Stem:** 0001104659-23-026699
**Filing Date:** 2023-2
**Character Count:** 28943
**Document Hash:** 98d353529ccee65eda3d1d672885b178
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-026699.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001104659-23-026699

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230228

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IOVANCE BIOTHERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001425205
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 753254381
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36860
- **FILM NUMBER:** 23685117

**BUSINESS ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD
- **STREET 2:** 4TH FLOOR
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070
- **BUSINESS PHONE:** 6502607120

**MAIL ADDRESS:**
- **STREET 1:** 825 INDUSTRIAL ROAD
- **STREET 2:** 4TH FLOOR
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lion Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20131015

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Genesis Biopharma, Inc
- **DATE OF NAME CHANGE:** 20100319

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FREIGHT MANAGEMENT CORP
- **DATE OF NAME CHANGE:** 20080128

?xml version="1.0" encoding="utf-8"?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K Current Report** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): February 28, 2023

**IOVANCE BIOTHERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Charter)

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**Delaware** |
| &nbsp;&nbsp;**(State of Incorporation)** | &nbsp;&nbsp;**(State of Incorporation)** |
| &nbsp;&nbsp;**001-36860** | &nbsp;&nbsp;**75-3254381** |
| &nbsp;&nbsp;**Commission File Number** | &nbsp;&nbsp;**(I.R.S. Employer Identification No.)** |
| &nbsp;&nbsp;**825 Industrial Road, 4th Floor** |  |
| &nbsp;&nbsp;**San Carlos, California** | &nbsp;&nbsp;**94070** |
| &nbsp;&nbsp;**(Address of Principal Executive Offices)** | &nbsp;&nbsp;**(Zip Code)** |
| &nbsp;&nbsp;**(650) 260-7120** | &nbsp;&nbsp;**(650) 260-7120** |
| &nbsp;&nbsp;**(Registrant's Telephone Number, Including Area Code)** | &nbsp;&nbsp;**(Registrant's Telephone Number, Including Area Code)** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Title of each class | &nbsp;&nbsp;Trading Symbol(s) | &nbsp;&nbsp;Name of each exchange on which registered |
| &nbsp;&nbsp;Common stock, par value $0.000041666 per share | &nbsp;&nbsp;IOVA | &nbsp;&nbsp;The Nasdaq Stock Market, LLC |

---

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.** |

---

On February 28, 2023, Iovance Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1.

The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [99.1](tm238068d1_ex99-1.htm) | [Press Release of Iovance Biotherapeutics, Inc., dated December 31, 2022.](tm238068d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 28, 2023 | **IOVANCE BIOTHERAPEUTICS, INC.** | **IOVANCE BIOTHERAPEUTICS, INC.** |
|  | By: | /s/ Frederick G. Vogt |
|  |  | Frederick G. Vogt, Interim CEO & General Counsel |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm238068d1_ex99-1img01.jpg)

**Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022**

**Financial Results and Corporate Updates**

 

*First Biologics License Application (BLA) Submission on Track to Complete in 1Q23*

**SAN CARLOS, Calif., February 28, 2023 --** Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported fourth quarter and full year 2022 financial results and corporate updates.

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "During 2022, we made considerable progress initiating our first BLA for lifileucel in advanced melanoma, preparing for launch, and advancing our immuno-oncology pipeline. As we prepare for commercialization and expand our pipeline, our planned acquisition of Proleukin<sup>®</sup> will provide an immediate source of revenue, streamline our supply chain and logistics, reduce our future cost of goods and lower expenses for IL-2 used with TIL therapies in commercial and clinical settings. Our top priorities in 2023 are to complete the BLA submission in the first quarter, receive FDA approval, then successfully launch lifileucel. We also continue to develop our pipeline in multiple solid tumor indications and look forward to presenting new data."

**Recent and Full Year 2022 Highlights and Corporate Updates**

**Acquisition of Proleukin<sup>®</sup>**

&nbsp;&nbsp;&nbsp;&nbsp;· Under
 a definitive <u>agreement</u> between Iovance and Clinigen Limited, Iovance will acquire
 worldwide rights to Proleukin<sup>®</sup> (aldesleukin), an interleukin-2 (IL-2) product
 with uses that include administration following TIL infusion to promote T-cell activity.
 Iovance expects the benefits of this transaction to include immediate and future revenue,
 securing the IL-2 supply chain and logistics surrounding TIL therapy administration, and
 lower cost of goods and clinical trial expenses for Proleukin<sup>®</sup> used with TIL
 therapies. The closing of this transaction is expected to occur by the end of the first quarter
 of 2023 or early in the second quarter of 2023, when all of the closing conditions and required
 regulatory approvals are achieved.

**Iovance TIL Therapy (Lifileucel) in Advanced Melanoma**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Regulatory highlights:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o A rolling BLA submission for lifileucel in post-anti-PD-1 advanced (metastatic
 or unresectable) melanoma <u>commenced</u> in August 2022 and remains on track to complete
 in the first quarter of 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Iovance received positive <u>feedback</u> from the U.S. Food and Drug
 Administration (FDA) on both its potency assay matrix and its proprietary cell co-culture
 assay included in the potency assay matrix in April 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o At a successful pre-BLA meeting in late July 2022, the FDA
 provided favorable <u>feedback</u> on the clinical efficacy data from Cohorts 2 and 4 of
 the C-144-01 clinical trial, including duration of follow up, and the potency assay matrix.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Startup activities have begun for the randomized Phase 3 <u>TILVANCE-301</u> trial after Iovance reached <u>agreement</u> with the FDA in the fourth quarter of 2022
 regarding the registrational trial design for accelerated and full approvals of lifileucel
 in combination with pembrolizumab in frontline advanced melanoma. TILVANCE-301, which is
 also a confirmatory trial to support full approval of lifileucel in post-anti-PD-1 advanced
 melanoma, is expected to be well underway at the time of potential accelerated approval for
 lifileucel in this initial indication.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **C-144-01 trial presentations and publications in post-anti-PD-1 advanced melanoma:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o **Society for Immunotherapy of Cancer (SITC) 37<sup>th</sup> Annual Meeting:** Iovance <u>presented</u> positive clinical data from Cohorts 2 and 4 of the
 C-144-01 clinical trial in advanced melanoma during SITC in November 2022 and in a subsequent
 companion <u>publication</u> in the *Journal for ImmunoTherapy of Cancer* (JITC).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **IOV-COM-202 (Cohort 1A) trial results in frontline advanced melanoma:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o In April 2022, Iovance <u>announced</u> updated positive Cohort 1A results
 for lifileucel in combination with pembrolizumab demonstrating a robust 67% ORR and durability
 of response in 12 patients. Safety was consistent with other studies of Iovance TIL therapies
 in combination with pembrolizumab.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o A January 2023 corporate update highlighted that results from nearly 20 patients treated in Cohort 1A remained consistent with previously
reported efficacy and safety data and continue to support the frontline melanoma opportunity for lifileucel. Study enrollment remains
ongoing.

**Manufacturing and Commercial Preparations**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· To date, more than 600 patients have been treated with Iovance TIL therapy
manufactured using proprietary Iovance processes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The
 Iovance Cell Therapy Center (<u>*i* CTC</u>) is currently
 manufacturing TIL therapies for clinical trials while executing activities to support BLA
 submission and review, including pre-approval inspection readiness, in preparation for initiating
 commercial supply.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The *i* CTC facility as currently built has annual capacity to supply
TIL therapies for 2,000+ patients, with available shell space that can be built to supply TIL therapies
for 5,000+ patients from this facility. Contract manufacturers provide additional flexibility and capacity for Iovance to meet potential
commercial and clinical demand.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Iovance is executing several initiatives ahead of potential commercialization,
including on-boarding and personnel training at authorized treatment centers (ATCs), education and awareness, and other commercial launch
readiness activities.

**Clinical Pipeline**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Iovance TIL (LN-145) monotherapy in second or third line metastatic non-small-cell lung cancer (mNSCLC):** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Enrollment is ongoing at more than 40 active clinical sites in the U.S.,
 Canada and Europe for the <u>IOV-LUN-202</u> trial of LN-145 in patients with mNSCLC who
 have progressed on or after frontline chemo- and anti-PD1-therapy. A Trial in Progress (TIP) <u>poster</u> was presented at the American Association for Cancer Research (AACR) Annual
 Meeting in April 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Iovance is engaged in discussions with the FDA about the potential for IOV-LUN-202 to serve as a registrational trial for LN-145 in
second/third line mNSCLC and intends to execute an updated regulatory strategy based on this dialogue and feedback.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Iovance TIL (LN-145) in combination with anti-PD-1 in earlier line mNSCLC:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Iovance reported positive initial <u>results</u> from Cohort 3A of the
 IOV-COM-202 clinical trial that explores the combination of TIL therapy (LN-145) and pembrolizumab
 as therapy for ICI naïve mNSCLC patients. A confirmed ORR by RECIST 1.1 of 47% (n=8/17)
 was observed, with responses observed across PD-L1 negative and positive patients.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Cohort 3A enrollment remains ongoing and presentation of detailed results is expected at a medical meeting in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o A meeting with the FDA is planned in 2023 to discuss Cohort 3A results and a potential registrational trial of lifileucel in frontline
advanced NSCLC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Iovance PD-1 inactivated TIL therapy (IOV-4001) in previously treated advanced melanoma or mNSCLC:** <u>The first patient</u> was treated with IOV-4001 in the third quarter of 2022 in the
 IOV-GM1-201 trial of Iovance's first genetically modified TIL therapy, IOV-4001. This
 is among the first clinical trials of a genetically modified TIL cell therapy for solid tumors.
 Study enrollment remains ongoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Lifileucel in advanced cervical cancer:** In 2022, Iovance updated the
registrational strategy in advanced cervical cancer based on FDA feedback to reflect the emerging treatment landscape. Cohort 2 in the
ongoing C-145-04 trial was expanded to be pivotal and began enrolling additional patients to support a BLA in cervical cancer following
progression on or after chemotherapy and pembrolizumab.

**Research Programs for Next-Generation TIL Therapies and Related Technologies**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· A
 preclinical <u>poster</u> at the AACR 2022 Annual Meeting in April highlighted
 the anti-tumor activity of IOV-4001 in a murine model of melanoma.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Additional programs using the gene editing TALEN<sup>®</sup> technology are expected
to enter clinical development in 2024, including genetically modified TIL therapy with multiple inactivated checkpoint targets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Additional <u>research</u> and preclinical studies are exploring approaches to increase TIL potency
 using CD39/69 double negative TILs and stable gene incorporation enhancements such as tethered
 cytokines.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· A novel interleukin-2 (IL-2) analog (IOV-3001) is in IND-enabling studies
supporting its use as part of the TIL treatment regimen following TIL infusion.

**Corporate**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· As of February 24, 2023, Iovance's unaudited cash position is approximately
$669.8 million, which includes net proceeds from an at-the market (ATM) equity financing facility of approximately $450.0 million raised
during the fourth quarter of 2022 and first quarter of 2023. This cash position is expected to fund the previously disclosed acquisition
of Proleukin<sup>®</sup> and Iovance's operating plan into the second half of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Iovance currently owns more than
 60 granted or allowed U.S. and international patents for TIL compositions and methods of
 treatment and manufacturing in a broad range of cancers ,
 with Gen 2 patent rights expected to provide exclusivity into 2038. More information on Iovance's
 patent portfolio can be found on the Intellectual Property page on <u>www.iovance.com</u>.

**Fourth Quarter and Full Year 2022 Financial Results**

Iovance had $478.3 million in cash, cash equivalents, investments and restricted cash at December 31, 2022, compared to $602.1 million at December 31, 2021. With the net proceeds from the ATM equity financing facility of approximately $450.0 million raised during the fourth quarter of 2022 and first quarter of 2023 to date, the cash position is expected to be sufficient to fund current and planned operations into the second half of 2024.

Jean-Marc Bellemin, Chief Financial Officer of Iovance, said, "Our cash position, including proceeds from our ATM facility, is expected to support our planned acquisition of Proleukin<sup>®</sup> as well as commercial launch preparations, internal manufacturing and clinical pipeline expansion into several milestones to create value for patients and shareholders."

Net loss for the fourth quarter ended December 31, 2022, was $105.3 million, or $0.64 per share, compared to a net loss of $99.3 million, or $0.63 per share, for the fourth quarter ended December 31, 2021. Net loss for the full year period ended December 31, 2022, was $395.9 million, or $2.49 per share, compared to a net loss of $342.3 million, or $2.23 per share, for the same period ended December 31, 2021.

Research and development expenses were $80.6 million for the fourth quarter ended December 31, 2022, an increase of $5.0 million compared to $75.6 million for the same period ended December 31, 2021. Research and development expenses were $294.8 million for the full year period ended December 31, 2022, an increase of $35.8 million compared to $259.0 million for the same period ended December 31, 2021.

The increases in research and development expenses in the fourth quarter and year-to-date 2022 over the prior year periods were primarily attributable to growth of the internal research and development team, including stock-based compensation expense, as well as facility-related and internal research program costs, which were partially offset by lower clinical and manufacturing costs driven by completion of enrollment of pivotal clinical trials.

General and administrative expenses were $26.5 million for the fourth quarter ended December 31, 2022, an increase of $2.7 million compared to $23.8 million for the same period ended December 31, 2021. General and administrative expenses were $104.1 million for the full year period ended December 31, 2022, an increase of $20.4 million compared to $83.7 million for the same period ended December 31, 2021.

The increase in general and administrative expenses in the fourth quarter and year-to-date 2022 compared to the prior year periods were primarily attributable to growth of the internal general and administrative and commercial teams, including stock-based compensation expense, and facility-related costs associated with the build-out of the new corporate headquarters, as well as costs associated with pre-commercial activities.

For additional information, please see the Company's Selected Condensed Consolidated Balance Sheet and Statement of Operations below.

**Webcast and Conference Call**

To participate in the conference call, please register at <u>https://edge.media-server.com/mmc/p/vku8d4ww</u>. The live and archived webcast can be accessed in the Investors section of the Company's website, IR.Iovance.com. The archived webcast will also be available for one year.

**About Iovance Biotherapeutics, Inc.**

<u>Iovance Biotherapeutics</u> aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The <u>Iovance TIL platform</u> has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit <u>www.iovance.com</u>.

**Forward-Looking Statements**

Certain matters discussed in this press release are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "forecast," "guidance," "outlook," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration ("FDA") or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, may support registrational studies and subsequent approvals by the FDA; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA (including from the recent pre-BLA meeting with the FDA); the risk that the rolling BLA submission for lifileucel in metastatic melanoma may take longer than expected; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that the acquisition of Proleukin<sup>®</sup> may not be completed in a timely manner or at all; the failure to satisfy the closing conditions to the consummation of the Proleukin<sup>®</sup> acquisition, including the receipt of all required regulatory approvals; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.

**IOVANCE BIOTHERAPEUTICS, INC.**

**Selected Consolidated Balance Sheets**

**(in thousands)**

---

| | | |
|:---|:---|:---|
|  | **December 31, 2022** | **December 31, 2021** |
| Cash, cash equivalents, and investments | $471845 | $595998 |
| Restricted cash | $6430 | $6084 |
| Total assets | $663982 | $777333 |
| Stockholders' equity | $499638 | $621659 |

---

**IOVANCE BIOTHERAPEUTICS, INC.**

**Consolidated Statements of Operations**

**(in thousands, except per share information)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Year Ended** | **For the Year Ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022<br> (unaudited)** | **2021<br> (unaudited)** | **2022** | **2021** |
| **Costs and expenses\*** |  |  |  |  |
| &nbsp;&nbsp;Research and development | $80573 | $75616 | $294781 | $259039 |
| &nbsp;&nbsp;General and administrative | 26463 | 23849 | 104097 | 83664 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total costs and expenses | 107036 | 99465 | 398878 | 342703 |
| **Loss from operations** | (107036) | (99465) | (398878) | (342703) |
| **Other income** |  |  |  |  |
| &nbsp;&nbsp;Interest income, net | 1717 | 135 | 2985 | 451 |
| **Net Loss** | $(105319) | $(99330) | $(395893) | $(342252) |
| **Net Loss Per Share of Common Stock, Basic and Diluted** | $(0.64) | $(0.63) | $(2.49) | $(2.23) |
| **Weighted Average Shares of Common Stock Outstanding, Basic and Diluted** | 164765 | 156923 | 159259 | 153406 |
| **\*Includes stock-based compensation expense as follows:** |  |  |  |  |
| &nbsp;&nbsp;Research and development | $11379 | $11542 | $50242 | $40833 |
| &nbsp;&nbsp;General and administrative | 8130 | 7562 | 33780 | 28932 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense | $19509 | $19104 | $84022 | $69765 |

---

**CONTACTS**

**Iovance Biotherapeutics, Inc.**:

Sara Pellegrino, IRC

SVP, Investor Relations & Corporate Communications

650-260-7120 ext. 264

<u>Sara.Pellegrino@iovance.com</u>

Jen Saunders

Director, Investor Relations & Public Relations

267-485-3119

<u>Jen.Saunders@iovance.com</u>